ReviewPergolide in the Treatment of Patients With Early and Advanced Parkinson's DiseaseBonuccelli, Ubaldo*; Colzi, Anna†; Del Dotto, Paolo‡Author Information *Department of Neuroscience, University of Pisa, Pisa; †Medical Department, Eli Lilly Italia, Florence; and ‡Department of Neurology, Versilia Hospital, Lucca, Italy Address correspondence and reprint requests to Ubaldo Bonuccelli, MD, Department of Neuroscience University of Pisa Via Roma, 67 56126 Pisa, Italy; E-mail: email@example.com. Clinical Neuropharmacology: January-February 2002 - Volume 25 - Issue 1 - p 1-10 Buy Abstract Introduced on the market in 1989, pergolide, a D1/D2 dopamine receptor agonist, is still widely prescribed for the treatment of patients with early and advanced Parkinson's disease (PD). Initially, pergolide was introduced as an adjunct therapy to levodopa treatment in patients exhibiting fluctuating motor responses and dyskinesias. Results of recent randomized controlled clinical trials in de novo patients with PD show that pergolide is able to improve parkinsonian symptoms when used as monotherapy. Moreover, preliminary results of a long-term monotherapy study in early PD suggest that pergolide is as effective as levodopa, and that a significant delay in the time of the onset of levodopa-induced motor complications can be obtained. A number of randomized studies have shown that pergolide is more effective than bromocriptine as adjunct therapy to levodopa in patients with advanced PD; the greater benefit found with pergolide could be ascribed to its action on both D1 and D2 dopamine receptors. However, controlled comparative studies with new dopamine agonists, such as ropinirole, cabergoline, and pramipexole, have not been performed yet. Interestingly, few open studies in patients with complicated PD have shown that high doses of pergolide (> 6 mg/d) are able to improve motor fluctuations and dyskinesias through a dramatic reduction of levodopa dosage. The side-effect profile of pergolide is similar to that of other dopamine agonists, and complications such as sleep attack and serosal fibrosis have been rarely reported. © 2002 Lippincott Williams & Wilkins, Inc.